Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
 
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company") has announced an exclusive agreement with Applied Biomedical Science Institute (ABSI) to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes. The goal is to develop proprietary multi-format biologics, including bi-specific antibodies, and antibody drug conjugates (ADCs), in order to combat drug-resistant cancers such as HER2-positive metastatic breast cancer, gastric cancer, lung cancer, and ovarian cancer.
 
The ErbB family of cell surface proteins, including ErbB2 or HER2 and Erb3 or HER3, are well-known oncology drug targets.